The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...

Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...

Zealand Pharma A/S (ZLDPF) shares ended the last trading session 8% higher at $72.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.25 per share a year ago.

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...